Rho to Coordinate NIAID Sponsored Study to Determine Rate of COVID-19 Infection in U.S. Children
Rho has announced it is coordinating a new study, called Human Epidemiology and Response to SARS-CoV-2 (HEROS), to help determine the rate of the new coronavirus infection in children and their family members in the U.S. The study also aims to determine what percentage of children infected with SARS-CoV-2, develop symptoms of the disease, as well as whether rates of SARS-CoV-2 infection differ between children who have asthma or other allergic conditions and children who do not. HEROS is sponsored and funded by the National Institute of Allergy and Infectious Diseases.
For more information, click
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025